OBJECTIVE: To analyse the effect of enrolment in the public health insurance scheme known as Seguro Popular [People's Insurance] on access to health resources, treatment and blood glucose control among poor adults with diabetes in Mexico. METHODS: We analysed cross-sectional data from the 2006 National Health and Nutrition Survey and compared health care access and biological health outcomes, specifically glycosylated haemoglobin (HbA1c) levels, among adults with diabetes who were enrolled in the Seguro Popular (treatment group) and those who had no health insurance (control group). Standard propensity score matching was used to create a highly comparable control group. FINDINGS: Adults with diabetes who were enrolled in the Seguro Popular had significantly more access than comparable uninsured adults to some type of blood glucose control test (by a difference of 9.5 percentage points; 95% confidence interval, CI: 2.4-16.6) and to insulin injections (3.13 more per week; 95% CI: 0.04-6.22). Those with insurance were also significantly more likely to have appropriately-controlled blood glucose levels (HbA1c <or= 7%) than their uninsured counterparts (by a difference of 5.6 percentage points; 95% CI: 0.9-10.3). Very poor glucose control (HbA1c > 12%) was found in a significantly smaller proportion of adults in the insured group than in the uninsured group (by a difference of 17.5 percentage points; 95% CI: 6.5-28.5). CONCLUSION: The Seguro Popular appears to have improved access to health care and blood glucose control among poor adults with diabetes in Mexico, and it may have had a positive effect on the management of other chronic health conditions, but its long-term effects are yet to be demonstrated. Although the findings are most relevant to Mexico, they may also be applicable to other developing countries seeking to improve health-care coverage for the poor by expanding their public health insurance programmes.
OBJECTIVE: To analyse the effect of enrolment in the public health insurance scheme known as Seguro Popular [People's Insurance] on access to health resources, treatment and blood glucose control among poor adults with diabetes in Mexico. METHODS: We analysed cross-sectional data from the 2006 National Health and Nutrition Survey and compared health care access and biological health outcomes, specifically glycosylated haemoglobin (HbA1c) levels, among adults with diabetes who were enrolled in the Seguro Popular (treatment group) and those who had no health insurance (control group). Standard propensity score matching was used to create a highly comparable control group. FINDINGS: Adults with diabetes who were enrolled in the Seguro Popular had significantly more access than comparable uninsured adults to some type of blood glucose control test (by a difference of 9.5 percentage points; 95% confidence interval, CI: 2.4-16.6) and to insulin injections (3.13 more per week; 95% CI: 0.04-6.22). Those with insurance were also significantly more likely to have appropriately-controlled blood glucose levels (HbA1c <or= 7%) than their uninsured counterparts (by a difference of 5.6 percentage points; 95% CI: 0.9-10.3). Very poor glucose control (HbA1c > 12%) was found in a significantly smaller proportion of adults in the insured group than in the uninsured group (by a difference of 17.5 percentage points; 95% CI: 6.5-28.5). CONCLUSION: The Seguro Popular appears to have improved access to health care and blood glucose control among poor adults with diabetes in Mexico, and it may have had a positive effect on the management of other chronic health conditions, but its long-term effects are yet to be demonstrated. Although the findings are most relevant to Mexico, they may also be applicable to other developing countries seeking to improve health-care coverage for the poor by expanding their public health insurance programmes.
Authors: Konrad Obermann; Matthew R Jowett; Maria Ofelia O Alcantara; Eduardo P Banzon; Claude Bodart Journal: Soc Sci Med Date: 2006-01-06 Impact factor: 4.634
Authors: David M Nathan; John B Buse; Mayer B Davidson; Robert J Heine; Rury R Holman; Robert Sherwin; Bernard Zinman Journal: Diabetes Care Date: 2006-08 Impact factor: 19.112
Authors: Emmanuela Gakidou; Rafael Lozano; Eduardo González-Pier; Jesse Abbott-Klafter; Jeremy T Barofsky; Chloe Bryson-Cahn; Dennis M Feehan; Diana K Lee; Hector Hernández-Llamas; Christopher J L Murray Journal: Lancet Date: 2006-11-25 Impact factor: 79.321
Authors: Emmanuela Gakidou; Leslie Mallinger; Jesse Abbott-Klafter; Ramiro Guerrero; Salvador Villalpando; Ruy Lopez Ridaura; Wichai Aekplakorn; Mohsen Naghavi; Stephen Lim; Rafael Lozano; Christopher J L Murray Journal: Bull World Health Organ Date: 2010-11-22 Impact factor: 9.408
Authors: Jawad A Al-Lawati; Mohammed N Barakat; Masoud Al-Maskari; Medhat K Elsayed; Alya M Al-Lawati; Ali Jaffer Mohammed Journal: Oman Med J Date: 2012-11
Authors: José Manuel Aburto; Hiram Beltrán-Sánchez; Victor Manuel García-Guerrero; Vladimir Canudas-Romo Journal: Health Aff (Millwood) Date: 2016-01 Impact factor: 6.301